CYCLOBENZAPRINE HYDROCHLORIDE TABLETS

The Defense Logistics Agency awarded a delivery order to DMS PHARMACEUTICAL GROUP INC under contract SPE2DX25D9900 for the supply of CYCLOBENZAPRINE HYDROCHLORIDE TABLETS, identified by NSN 6505010628010 and NDC 72789-0036-01. The total contract value is $188.04 for four bottles delivered under CLIN 0001, with FOB destination terms placing freight and payment responsibility on the contractor. Delivery is scheduled for August 5, 2026, to Fort Bliss, Texas, with inspection and acceptance occurring at the destination. The packaging must include the manufacturer’s CAGE code and NDC label, and shipments must use traceable methods—parcel post is prohibited. No explicit packaging standards like MIL-STD-129 or MIL-STD-2073 are referenced, nor are bar-coding requirements specified. The contract is a firm-fixed-price delivery order with no options, extensions, or additional line items. The award date is July 21, 2026, and the solicitation number is SPE2DP26F7899. Government use codes A0A and Z9, along with PR number 7017578606, are included for internal accounting. No payment office, contracting officer, or COR details are provided, and the invoicing method remains unspecified. The awardee’s CAGE code is 1UNB0, and while manufacturer CAGE codes are listed, no socioeconomic status, size certification, or unique entity ID is disclosed. Section I of the contract containing FAR clauses, Section J listing attachments, and Section M detailing evaluation factors were not included in the documentation. No security clearances, key personnel requirements, or organizational conflict of interest provisions are stated. The product is presumed to meet FDA and USP standards by virtue of its pharmaceutical nature and distribution through DoD channels, though no explicit compliance requirements are stated. All contract data is limited to this single-line item with no reference to additional clauses, modifications, or administrative instructions beyond delivery and labeling guidelines.